Adherence to BCR-ABL inhibitors: issues for CML therapy.

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Chronic myeloid leukemia (CML) treatment has advanced with oral BCR-ABL inhibitors.
• Lifelong therapy is often required for CML management.
• Medication adherence is a critical challenge in managing chronic conditions like CML.

Purpose of the Study:

• To highlight the importance of medication adherence in CML patients on BCR-ABL inhibitors.
• To discuss the prevalence and consequences of nonadherence.
• To identify factors influencing adherence and suggest strategies for improvement.

Main Methods:

• Review of existing literature on CML treatment and medication adherence.
• Analysis of factors contributing to nonadherence in CML patients.
• Discussion of clinical implications of adherence and nonadherence.

Main Results:

• Nonadherence is common in CML, affecting one-third or more of patients.
• Reduced adherence to BCR-ABL inhibitors is linked to decreased treatment efficacy.
• Nonadherence is associated with increased healthcare utilization and costs.

Conclusions:

• Physicians must address and monitor factors influencing adherence, such as dose, toxicity, and concomitant medications.
• Individualizing CML treatment and simplifying regimens can maximize patient adherence.
• Optimizing adherence is crucial for long-term CML management and patient outcomes.